Notes

Long-term usefulness and adverse effects associated with ketogenic diet regime treatment within babies with drug-resistant epilepsy treated at a individual center within Argentina.
Patients with small core infarction and salvageable penumbra are likely to benefit from endovascular treatment (EVT). As computed tomography perfusion imaging (CTP) is not always available 24/7 for patient selection, many patients are transferred to stroke centers for CTP. We compared automatically measured infarct core volume (NCCT
) from the non-contrast computed tomography (NCCT) with ischemic core volume (CTP
) from CTP and the outcome of EVT to clarify if NCCT
measurement alone is sufficient to identify patients that benefit from transfer to stroke centers for EVT.

We included all consecutive stroke-code patients imaged with both NCCT and CTP at Helsinki University Hospital during 9/2016-01/2018. NCCT
and CTP
volumes were automatically calculated from the acute NCCT images. Follow-up infarct volume (FIV) was measured from 24h follow-up NCCT to evaluate efficacy of EVT. To study whether NCCT
could be used to identify patients eligible to EVT, we sub-grouped patients based on NCCT
volumes (>50mL and≥70mL).

Out of 1743 patients, baseline NCCT
, CTP
and follow-up NCCT was available for 288 patients. Median time from symptom onset to baseline imaging was 74min (IQR 52-118), and time to follow-up imaging 24.15h (22.25-26.33). Baseline NCCT
was 20mL (10-42), CTP
4mL (0-16), and FIV 5mL (1-49). Out of 288 patients, 23 had NCCT
≥70mL and 26 had CTP
≥70mL. NCCT
and CTP
performed similarly well in predicting large FIV (≥70ml).

NCCT
is a promising tool to identify patients that are not eligible to EVT due to large ischemic cores at baseline imaging.
NCCTcore is a promising tool to identify patients that are not eligible to EVT due to large ischemic cores at baseline imaging.Classical theories of intersubjectivity hold that the first interactions in which children participate are dyadic (adult-baby). However, thanks to the material shift that is taking place in the cognitive sciences, an increasing number of authors began to recognise the constitutive role that materiality has for cognition, from the very beginning of life. Interactions do not occur in a vacuum, but within a meaning-loaded material world that adults actively seek to bring to children. While in the field of dyadic interactions studies on communicative musicality have shown how interactive exchanges are structured and how that structure unfolds over time, little is known yet about the internal structure of early triadic interactions. In this paper, we propose a longitudinal, mixed and multilevel methodological framework aimed at describing the dynamics of the musical organisation of early triadic interactions between adults, babies and things, and its development over different timescales. We conclude that if researchers want to fully understand early triadic interactions and their musical structuring, further studies that take into account the cognitive relevance of things and the dynamics of our interactions with and through materiality are needed.
Based on recent pharmacokinetic/pharmacodynamic (PK/PD) evidence, continuous-infusion (CI) β-lactam administration is increasingly recommended for serious infections. Since 2016, the combination ceftazidime/avibactam (CAZ/AVI) is administered as per the manufacturer's instructions as an intermittent infusion of 2.5 g every 8 h. Thus, CI has not yet been evaluated in clinical trials.

We aimed to evaluate the use of CI of CAZ/AVI in a retrospective case series from December 2016 to October 2019. All isolates displayed in vitro susceptibility to CAZ/AVI according to EUCAST definitions. Patients were initially given CAZ/AVI as CI of 5 g every 12 h, and dosages were adjusted according to therapeutic drug monitoring of ceftazidime with a therapeutic goal of ≥4-5×MIC in plasma and/or at the site of infection.

CAZ/AVI was administered by CI in 10 patients with infections mainly caused by multidrug-resistant Pseudomonas aeruginosa (54.5%) and Klebsiella pneumoniae (36.4%). Bacteraemia occurred in 30% of cases. Sepsis or septic shock was present in 20% of cases. CAZ/AVI was used as monotherapy in 60% of cases. Clinical cure and microbiological eradication were achieved in 80% and 90% of cases, respectively. The 30-day mortality after CAZ/AVI treatment onset was 10%. The therapeutic goals of ≥4-5×MIC in plasma and/or at the site of infection were achieved in 100% and 87.5% of cases, respectively, without adverse events.

Despite a limited number of patients, CI of CAZ/AVI provided promising results after optimisation of PK/PD parameters both in plasma and at the site of infection.
Despite a limited number of patients, CI of CAZ/AVI provided promising results after optimisation of PK/PD parameters both in plasma and at the site of infection.
This study aimed to evaluate the efficacy and safety of oritavancin (ORI) versus comparators for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) based on available clinical studies.

PubMed, Cochrane Library and Embase were searched from database inception to 28 July 2020 to identify clinical studies assessing the efficacy and safety of ORI and comparator antibiotics for the treatment of ABSSSIs. Primary efficacy outcome, investigator-assessed clinical cure, lesion size reduction ≥20%, additional post-treatment antibiotics, and 30-day emergency room (ER) visits and readmission were assessed as efficacy outcomes. Adverse events (AEs) and mortality were assessed as safety outcomes. I
statistic was calculated for heterogeneity, and a fixed-effects or random-effects model was used for estimation of the risk ratio (RR).

A total of 9213 patients from two randomised clinical trials (RCTs) and four cohort studies were included in this meta-analysis. ORI was statistically non-inferior to control agents in all efficacy and safety outcomes. Moreover, ORI significantly reduced the occurrence of 30-day readmission (RR=0.42; P=0.0004) and drug-related AEs (RR=0.78; P=0.002). In the subgroup analysis, ORI also had a lower rate of 30-day ER visits in the outpatient setting (RR=0.34; P < 0.00001).

ORI was not inferior to comparators for the treatment of ABSSSIs. Meanwhile, it showed advantages in reducing the rate of readmission and drug-related AEs. More high-quality and large-scale RCTs are required to further confirm the efficacy and safety of ORI. [Trial registration PROSPERO ID CRD42020201942].
ORI was not inferior to comparators for the treatment of ABSSSIs. Meanwhile, it showed advantages in reducing the rate of readmission and drug-related AEs. Pluronic F-68 More high-quality and large-scale RCTs are required to further confirm the efficacy and safety of ORI. [Trial registration PROSPERO ID CRD42020201942].
Read More: https://www.selleckchem.com/products/pluronic-f-68.html